TCM
XENT

Tekla Capital Management’s Intersect ENT, Inc XENT Stock Holding History

Tekla Capital Management’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-8,356
Closed -$240K – 215
2018
Q3 		$240K Buy
+8,356
New +$251K 0.01% 208

Other funds holding XENT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Tekla Capital Management's XENT Position: Q4 2018 in Review

Tekla Capital Management sold out of Intersect ENT, Inc (XENT) in Q4 2018, closing a stake of 8,356 shares — an estimated $240K sold.

Tekla Capital Management first reported a position in XENT in Q3 2018 and held it in 1 quarter. The position peaked at $240K in Q3 2018. 136 funds tracked by Wall St. Rank hold XENT as of Q4 2018.

  • Tekla Capital Management reported no remaining Intersect ENT, Inc position as of Q4 2018 after selling out during the quarter.
  • Tekla Capital Management sold 8,356 Intersect ENT, Inc shares in Q4 2018, an estimated $240K.
  • Tekla Capital Management first reported a position in Intersect ENT, Inc in Q3 2018 and held it in 1 quarter.
  • Tekla Capital Management's Intersect ENT, Inc position peaked at $240K in Q3 2018.
  • 136 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q4 2018.

Based on Tekla Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.